Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient advanced breast and ovarian cancer in women without inherited BRCA1 or BRCA2 mutations

Olaparib is known to be effective treatment for breast and ovarian cancers in people with inherited mutations. Many more patients do not have a genetic risk but have cancers arising from spontaneous mutations. Our clinical trial aims to find out whether olaparib benefits patients with breast or ovarian cancers with non-inherited mutations or abnormalities.